Form 8-K
8-K — Valion Bio, Inc.
Accession: 0001683168-26-008221
Filed: 2026-11-02
Period: 2026-10-27
CIK: 0001787740
SIC: 2834 (PHARMACEUTICAL PREPARATIONS)
Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item: Other Events
Item: Financial Statements and Exhibits
Documents
8-K — valion_8k.htm (Primary)
EX-10.1 — SEPARATION AGREEMENT (valion_ex1001.htm)
EX-99.1 — PRESS RELEASE, DATED OCTOBER 30, 2026 (valion_ex9901.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K — FORM 8-K
8-K (Primary)
Filename: valion_8k.htm · Sequence: 1
Tivic Health Systems, Inc. Form 8-K
false
0001787740
0001787740
2026-10-27
2026-10-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date
of earliest event reported): October 27, 2026
Valion
Bio, Inc.
(Exact name of Registrant as Specified in Its
Charter)
Delaware
001-41052
81-4016391
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
1305 E. Houston Street,
Building 1, Suite 311
San Antonio, Texas
78205
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 888
276-6888
Not applicable.
(Former name or former address, if changed since
last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value
$0.0001 per share
VBIO
The Nasdaq Stock
Market LLC
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Item 5.02(b)
On October 27, 2026, Valion Bio, Inc. (the “Company”)
notified Melinda Lackey, the Company’s General Counsel and Senior Vice President of Legal Affairs, of the termination of her employment,
effective October 30, 2026.
Item 5.02(e)
On October 31, 2026, the Company entered into
a Separation Agreement and General Release (the “Separation Agreement”) with Melinda Lackey.
Under the Separation Agreement, subject to Ms.
Lackey’s compliance with its terms and the satisfaction of the conditions set forth therein, the Company agreed to pay Ms. Lackey
a gross cash severance payment of $26,750, less applicable taxes and withholdings, in a single lump-sum payment no later than 30 days
following the effective date of the Separation Agreement.
In addition, if Ms. Lackey is eligible for and
properly elects continued medical or dental coverage under COBRA, the Company agreed to pay the applicable COBRA premiums for Ms. Lackey
and her covered dependents until the earlier of November 30, 2026 or the date on which she becomes eligible for healthcare coverage under
a subsequent employer’s health plan.
The Separation Agreement also provides for a general
release of claims by Ms. Lackey in favor of the Company and certain related parties and includes customary confidentiality, non-disparagement,
cooperation, return-of-property and other continuing obligations. Ms. Lackey agreed to forfeit any unvested equity awards and may exercise
any vested stock options only in accordance with the applicable equity plan documents.
The foregoing description of the Separation Agreement does not purport
to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, which is filed as Exhibit 10.1
to this Current Report on Form 8-K and incorporated herein by reference.
2
Item 8.01 Other Events.
On October 30, 2026, Valion Bio, Inc. (the “Company”)
announced the evaluation of its lead biologic drug candidate, Entolimod, by the Armed Forces Radiobiology Research Institute in connection
with research relating to gastrointestinal acute radiation syndrome in a therapeutic efficacy study.
A copy of the Company’s press release is
attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number
Description
10.1
Separation Agreement and General Release, by and between Valion Bio, Inc. and Melinda Lackey.
99.1
Press Release, dated October 30, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
* Certain personal information has been omitted
from this exhibit pursuant to Item 601(a)(6) of Regulation S-K.
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
VALION BIO, INC.
Date:
November 2, 2026
By:
/s/ Dean Zikria
Name: Dean Zikria
Title: Interim Chief Executive Officer
3
EX-10.1 — SEPARATION AGREEMENT
EX-10.1
Filename: valion_ex1001.htm · Sequence: 2
Exhibit 10.1
Certain personal information has
been omitted from this exhibit pursuant to Item 601(a)(6) of Regulation S-K. The omitted information is indicated by “[***]”
SEPARATION AGREEMENT AND
GENERAL RELEASE
This Separation
Agreement and General Release (the “Agreement”) is entered into by and between Melinda Lackey (“Employee”), on
Employee’s behalf and on behalf of Employee’s heirs, executors, administrators, successors and assigns (collectively, “Releasor”),
and Valion Bio, Inc. (formerly known as Tivic Health Systems, Inc.) (the “Employer”). Employee and Employer are each referred
to herein as a “Party” and collectively as the “Parties.”
WHEREAS, Employee was employed
by the Employer as the General Counsel and Senior Vice President of Legal Affairs;
WHEREAS, Employee executed
an employment agreement with Employer on May 1, 2026, and any accompanying employee invention assignment, confidentiality agreement, and
arbitration agreement, attached thereto or otherwise (collectively, the “Employment Agreement”);
WHEREAS, Employee’s
employment with Employer ended on October 30, 2026 (the “Separation Date”);
WHEREAS, the
Parties desire to fully and finally resolve and settle any and all issues between them, actual or potential, through a release of all
claims against Releasees (as defined in Paragraph 4 below) and the other promises contained herein;
NOW, THEREFORE,
in consideration of the promises and mutual covenants contained herein, and for other good and valuable consideration, the receipt and
sufficiency of which are expressly acknowledged, the Parties, intending to be legally bound, agree as follows:
1.Recitals. The Parties acknowledge and agree that the Recitals set forth above are true and accurate and are incorporated
herein by this reference.
2.Separation. Employee acknowledges that after the Separation Date, Employee shall have no further job duties or responsibilities
as an employee of the Employer. Employee further understands and agrees that after the Separation Date, Employee will no longer be authorized
to incur any expenses, liabilities, or obligations on behalf of the Employer and may not, under any circumstance, act as, or represent
that Employee has the authority to act as, an agent for the Employer.
1
3. Severance.
(a)
In consideration of the promises and mutual covenants set forth herein—including, without limitation, satisfaction of the
responsibilities identified in Paragraphs 8 and 12 below, at the Employer’s sole discretion—and for other good and valuable
consideration, the receipt and sufficiency of which are expressly acknowledged, Employee will accept, on Employee’s behalf and on
behalf of Releasor, a separation payment in the total gross amount of Twenty-Six Thousand Seven Hundred Fifty Dollars and Zero Cents ($26,750.00),
minus applicable withholdings and deductions (the “Severance”). Subject to the terms of this Agreement, the Severance shall
be paid to Employee in the form of a one-time lump-sum payment, which shall be remitted to Employee, in the same manner as that by which
Employee’s compensation had been remitted to Employee, by no later than thirty (30) days after the “Effective Date”
of this Agreement, as that term is defined below, provided that Employee executes, and does not revoke, this Agreement. The monies contemplated
under this Paragraph 3(a) shall be reported to the Internal Revenue Service (and applicable state and local tax authorities) by way of
an IRS Form W-2.
(b)
In the event that Employee is eligible to elect, and properly elects, healthcare continuation coverage (medical and/or dental)
under the Employer’s group health plans pursuant to COBRA, Employer shall directly pay to the applicable insurance carrier the COBRA
premiums for Employee and Employee’s covered dependents, if any (such payments, the “COBRA Payments”), until the earlier
of November 30, 2026 or the date on which Employee becomes eligible for healthcare coverage under a subsequent employer’s health
plan (the “COBRA Period”). Upon the earlier of November 30, 2026 or the date on which Employee becomes eligible for healthcare
coverage under a subsequent employer’s health plan, Employee shall become solely responsible for the payment of any and all COBRA
premiums which Employer had been paying as described above.
(c)
Employee acknowledges and agrees that (i) the Severance and COBRA Payments described in Paragraphs 3(a) and 3(b) above constitute
adequate consideration for all of the terms of this Agreement; (ii) Employee will not be entitled to any other compensation or benefits
from the Employer, except as expressly provided for in this Agreement; and (iii) Employee specifically waives and forgoes all rights to
any compensation or benefits of any kind that are not expressly provided to Employee under this Agreement.
(d)
In addition to the payments set forth above, as applicable, Employer shall pay to Employee after the Separation Date all unpaid
wages through the Separation Date, which shall be reduced by any and all applicable taxes and withholdings (such payment, the “Required
Payment”). Employee agrees that, subject to the Employer’s obligation, if any, to provide the Severance and COBRA Payments,
once the Required Payment has been made, any wages, salary, commissions, bonuses, compensation, or other benefits, whether monetary or
otherwise, to which Employee may have been entitled, whether by operation of law, contract, policy, or otherwise, will have been paid,
or such payments are released, waived, or settled by Employee pursuant to this Agreement.
2
4. Release and Waiver of Claims.
THIS PARAGRAPH PROVIDES A COMPLETE
RELEASE AND WAIVER OF ALL EXISTING AND POTENTIAL CLAIMS EMPLOYEE MAY HAVE AGAINST EVERY PERSON AND ENTITY INCLUDED WITHIN THE DESCRIPTION
BELOW OF “RELEASEES.” BEFORE YOU SIGN THIS AGREEMENT, YOU MUST READ THIS ENTIRE PARAGRAPH 4 CAREFULLY, AND MAKE SURE THAT
YOU UNDERSTAND IT FULLY.
(a)
For valuable consideration, including the Severance and COBRA Payments, the receipt and adequacy of which are hereby acknowledged,
Releasor does hereby unconditionally and generally release and forever discharge Employer, Velocity BioWorks, Inc., and each of their
current and former partners, associates, affiliates, subsidiaries, predecessors, successors, heirs, assigns, agents, directors, officers,
employees, members, representatives, board members, investors, advisors, lawyers, insurers, and all persons acting by, through, under,
or in concert with them, or any of them (collectively, “Releasees”), of and from any and all manner of action or actions,
cause or causes of action, in law or in equity, suits, debts, liens, liability, claims, demands, damages, losses, costs, attorneys’
fees or expenses, of any nature whatsoever, known or unknown, fixed or contingent, which Releasor now has or may hereafter have against
the Releasees, or any of them, by reason of any matter, cause, or thing whatsoever arising from the beginning of time to the date on which
Employee shall have executed this Agreement (collectively, the “Claims”).
(b)
The Claims released herein include, without limiting the generality of the foregoing, any Claims in any way arising out of, based
upon, or related to Employee’s employment by Releasees, or any of them, or the termination or cessation thereof; any claim for wages,
salary, commissions, bonuses, incentive payments, profit-sharing payments, expense reimbursements, leave, vacation, severance pay or other
benefits and/or compensation of any kind; any alleged breach of any express or implied contract or agreement; any claim arising under
any employment contract or other employment arrangement, whether express or implied, written or oral; any alleged torts or other alleged
legal restrictions on any Releasee’s right to terminate Employee’s employment; any alleged violation of any federal, state
or local statute or ordinance including, without limitation, Title VII of the Civil Rights Act of 1964, the Age Discrimination in Employment
Act, the Equal Pay Act, the Family and Medical Leave Act, the Americans With Disabilities Act, the Employee Retirement Income Security
Act, the Worker Adjustment and Retraining Notification Act, the National Labor Relations Act, Texas Labor Law, and the Texas Commission
on Human Rights Act, each as amended; and any claim for tortious or harassing conduct, infliction of mental distress, interference with
contract, fraud, libel or slander. Employee further waives any right Employee may have to recover monetary damages in connection with
a claim or charge brought on Employee’s behalf by the U.S. Equal Employment Opportunity Commission (“EEOC”) or any similar
state or local agency. Notwithstanding the foregoing, this Agreement shall not operate to release any Claims which Releasor may have with
respect to (i) any vested amounts due under or with respect to any benefit plan, if any; (ii) enforcement of the Agreement; (iii) a charge
or claim with the EEOC or any other local, state, or federal regulatory or law enforcement agency; and (iv) claims that cannot be released
as a matter of law.
(c)
Employee represents and warrants that there has been no assignment or other transfer of any interest in any Claim which any Releasor
may have against the Releasees, or any of them, and Releasor agrees to indemnify and hold the Releasees, and each of them, harmless from
any liability, Claims, demands, damages, costs, expenses and attorneys’ fees incurred by the Releasees, or any of them, as the result
of any such assignment or transfer of any rights or Claims. It is the intention of the Parties that this indemnity does not require payment
as a condition precedent to recovery by the Releasees against any Releasor under this indemnity.
(d)
Releasor expressly understands and acknowledges that it is possible that unknown losses or claims exist or that present losses
may have been underestimated in amount or severity, and Releasor explicitly took that into account in assessing the consideration underlying
this Agreement, and a portion of said consideration and the mutual covenants hereunder were given in exchange for a full satisfaction
and discharge of any and all Claims.
3
5.Covenant Not to Sue. Employee represents and warrants that Releasor has not filed or commenced any complaints, claims, actions,
grievances, or proceedings of any kind (collectively for purposes of this Paragraph 5, “Actions”) against any of the Releasees
with any court or any administrative, regulatory, or other agency or body, including, without limitation, an arbitral body, in connection
with any Claims released under Paragraph 4, above. In the event such Actions have been filed, this Agreement shall render them, and hereby
renders them, irrevocably null, void, withdrawn, and dismissed with prejudice. To the fullest extent permitted by law, Employee agrees
not to commence, maintain, prosecute, or participate in any action or proceeding of any kind against the Employer or any other Releasee
with respect to any act, omission, or occurrence up to and including the date on which Employee shall have executed this Agreement. Employee
agrees that if any Releasor hereafter commences any Action arising out of, based upon, or relating to any of the Claims released in this
Agreement or in any manner asserts against the Releasees, or any of them, any of the Claims released hereunder or any claim challenging
the enforceability of any provision of this Agreement, then Releasor shall, in addition to any other damages caused to the Releasees thereby,
be required, and agrees, to repay to Employer the entirety of the Severance. Nothing herein shall prevent Employee from raising or asserting
any defense in any suit, claim, proceeding or investigation brought by any of the Releasees, and by raising or asserting any such defense,
Employee shall not become obligated to pay attorneys’ fees under this Paragraph 5. Subject to applicable law, including, without
limitation, laws promulgated by or on behalf of the Securities and Exchange Commission, in the event that any third party, including,
without limitation, a government agency, seeks to obtain any relief on behalf of any Releasor with regard to any Claim released and waived
in this Agreement, Releasor covenants not to accept or receive any monetary relief or award that may arise out of or in connection with
any such proceeding. Employee acknowledges that different or additional facts may be discovered in addition to what is now known or believed
to be true by Employee with respect to the matters released in this Agreement, and Employee agrees that this Agreement shall be and remain
in effect in all respects as a complete and final release of the matters released, notwithstanding any different or additional facts.
6.Confidentiality of Agreement. Except as may be required by law, Employee shall keep confidential and shall not disclose
to any person (other than to Employee’s immediate family, attorney and accountant, each of whom shall be directed by Employee not
to disclose such information), any and all information concerning the existence or terms of this Agreement, except in the circumstance
of (i) Employee’s truthful testimony in court or an administrative tribunal; (ii) providing information in response to a subpoena
or order issued by a court or a government agency; and/or (iii) as otherwise required by law, including, without limitation, under the
National Labor Relations Act.
7. Arbitration Relating to this Agreement. Employee agrees that any dispute or controversy between the Parties in any way arising out of, related to, or connected with this Agreement itself shall be resolved through final and binding arbitration in New York, New York, pursuant to the Employment Arbitration Rules and Procedures of JAMS, Inc. (“JAMS”), available at www.jamsadr.com. In the event of a dispute subject to this section, the parties shall be entitled to written discovery and depositions adequate to give the parties access to documents and witnesses that are essential to the dispute, subject to the discretion of the arbitrator and pursuant to the applicable JAMS rules. The arbitrator selected shall have the authority to grant either party or both all remedies otherwise available by law, including injunctions. The arbitrator shall render an award and written opinion explaining the basis for the award. The arbitral award shall be binding upon the parties. Judgment upon the award rendered by the arbitrator may be entered in any court having competent jurisdiction thereof. Both parties shall take all reasonable steps to maintain the confidentiality of the arbitration award, including executing a confidentiality stipulation in a form acceptable to Employer. The prevailing party in such arbitration, as determined by the arbitrator, and in any enforcement or other court proceedings, shall be entitled, to the extent permitted by law, to reimbursement from the other party for all of the prevailing party’s costs (including but not limited to the arbitrator’s compensation), expenses, and attorneys’ fees, in accordance with applicable law. Provided, however, Employer shall pay for all costs which are unique to the arbitration process, if required by applicable law. The Parties acknowledge that by agreeing to arbitration pursuant to this section, they are waiving their right to a judicial forum and to a trial by jury. The Parties agree that Employer is engaged in interstate commerce and that, except as provided in this Agreement, the Federal Arbitration Act (“FAA”) shall govern the interpretation and enforcement of, and all proceedings pursuant to, this Agreement.
4
8. Return of Confidential Information and Employer Property.
(a)
Employee agrees that Employee will return to the Employer all Confidential Information in Employee’s possession or otherwise
under Employee’s control, in whatever format, whether written, recorded, electronically or digitally stored and/or retrieved, no
later than two (2) days after the Separation Date, and Employee agrees not to retain any copies of any and all documents, records, or
materials of any kind, whether written or electronically created or stored, which contain, relate to, or refer to any Confidential Information.
It is understood and agreed that Employee’s above-described return and non-retention of the Employer’s Confidential Information
is a material condition of this Agreement.
(b)
Employee agrees that, no later than two (2) days after the Separation Date, Employee will return to the Employer any and all Employer
property and equipment of any kind, including, but not limited to, access passwords relating to work Employee performed for Employer,
keys, mobile communication devices, computer equipment, files, documents, and the like (“Employer Property”).
(c)
Notwithstanding the foregoing, Employer has agreed to permit Employee to maintain possession of Employee’s Employer-provided
laptop. No later than five (5) days after November 30, 2026, Employee shall provide written confirmation that she has wiped all Employer
Confidential Information, Employer software, and Employer data off of this laptop.
9. Non-Admission; Non-Disparagement.
(a)
Neither this Agreement, nor the Severance or COBRA Payments, is intended to be, shall be construed as, or is, an admission or concession
by any of the Releasees of any wrongdoing, error, liability, or actionable acts or omissions, and the Releasees expressly deny that any
of them has engaged in any wrongdoing, error, or actionable acts or omissions.
(b)
Employee, as and on behalf of Releasor, hereby represents and agrees that Releasor shall not directly or indirectly (i) make any
written or oral statements, suggestions or representations that the Employer or any Releasee has made or implied any admission or concession
contemplated in Paragraph 9(a), above; and/or (ii) except as may be required by law, make any oral or written defaming, disparaging, negative,
or knowingly or maliciously false statements, suggestions, or representations of or concerning the Employer or any Releasee. For the avoidance
of doubt, this includes, without limitation, statements, suggestions, or representations memorialized in any medium whatsoever, whether
electronic or otherwise, including, without limitation, e-mail and social media platforms of any kind. Employee acknowledges and agrees
that violating this non-disparagement clause would constitute a material breach of this Agreement.
10.Surviving Terms of Employment Agreement. Employee acknowledges that certain terms contained in the Employment Agreement
will survive the termination of her employment with Employer. Employee understands and agrees that she will continue to be subject to,
and abide by, such terms after the Separation Date. To the extent there is a conflict between any term or provision contained in this
Agreement and the Employment Agreement, the term or provision most favorable to the Employer shall apply.
11.Equity Grants. Employee acknowledges and agrees that by virtue of this separation, Employee is forfeiting any unvested equity,
if any, pursuant to the applicable plan documents. Additionally, Employee may exercise any vested options consistent with applicable plan
documents only.
5
12.Future Cooperation.
(a)
Employee agrees that after the Separation Date, Employee shall cooperate with, and shall be available to, the Employer to assist
in any matter, including, without limitation, transitioning her duties and providing information regarding relevant operations, processes,
materials, passwords, insights, projects on which she was working prior to the Separation Date, access to files, and/or the location of
relevant information, and assisting government agency investigations and actual or potential court litigation or arbitration in connection
with which Employee may have knowledge. If Employee receives a subpoena or process from any person or entity (including, but not limited
to, any governmental agency) which would or may require Employee to disclose documents or information or provide testimony (in a deposition,
court proceeding, or otherwise) regarding, in whole or in part, any of the Releasees or any proprietary or confidential information, Employee
shall: (i) notify the Employer of the subpoena or other process within two (2) business days of receiving it (or a shorter period such
that not less than one (1) business day shall remain between such notification and any deadline for response thereto); and (ii) to the
maximum extent permissible under applicable law, not make any disclosure until the appropriate Releasees have had a reasonable opportunity
to contest the right of the requesting person or entity to such disclosure, limit the scope or nature of such disclosure, and/or seek
to participate in the proceeding or matter in which the disclosure is sought. Employee shall further cooperate with Employer in responding
to any such subpoena or process.
(b)
In addition to the foregoing, no later than two (2) days following the Separation Date, Employee shall (i) transfer administrative
rights and passwords for the systems Employee administered during her employment, including, without limitation, Paylocity, Empower, Beneflex,
DocuSign, ContractSafe and ShareFile; and (ii) provide a short written list of open legal matters and upcoming deadlines, including, without
limitation, the following:
·
the Bexar County lawsuit (Snell)
·
the CG Capital / Rich matter
·
patent counsel matters (Dentons, Launchpad, Snell)
·
the Handley proxy item, the Snell-to-Venable transition and the AFRRI agreement
·
pending 8-Ks, minutes and consents
13.Notices. Any notices or transmissions to be given hereunder by either party to the other may be effected by (a) personal
delivery in writing; (b) nationally recognized overnight delivery service; or (c) electronic mail. Notices shall be addressed to the parties
at the following addresses:
(a) If to the Employer, to:
Dean Zikria
Interim CEO
Valion Bio, Inc.
1305 E. Houston Street, Building 1, Suite 311
San Antonio, TX 78205
dean.zikria@valionbio.com
With a copy to:
William Haddad, Esq.
Venable LLP
151 W. 42nd Street, 49th Floor
New York, New York 10036
WNHaddad@Venable.com
(b) If to Employee, to:
Melinda Lackey
[***]
Either Party may change its above-noted
contact information by written notice in accordance with this Paragraph 13. Notice delivered personally will be deemed communicated as
of actual receipt, and notices sent by overnight delivery service will be deemed communicated as of the business day after sending.
6
14.Entire Agreement, Amendment, and Choice of Law. This Agreement, together with the Employment Agreement, constitutes the
sole and complete understanding and agreement between the Parties concerning the subject matter hereof. This Agreement supersedes any
previous agreements and/or understandings, whether formal or informal, and whether written or oral, between the Parties or between Employee
and the Employer regarding the subject matter hereof, except the Employment Agreement, and except as otherwise provided herein. This Agreement
may not be amended except in a writing signed by both Parties. Except as otherwise provided under the FAA or other applicable law, this
Agreement shall be governed by and construed in accordance with the laws of the State of Texas, without regard to its conflicts of laws
provisions.
15.Successors. For the avoidance of doubt, and without limiting any other provision of this Agreement, the rights, remedies,
and protections afforded to the Employer hereunder, including the rights, remedies, and protections set forth in Paragraph 4 herein, shall
inure to the benefit of the Employer’s current and former parents, subsidiaries, representatives, successors, and administrators.
16.Severability. If any provision of this Agreement is declared or determined by any court to be illegal or invalid, that part
shall be modified or excluded from this Agreement only to the extent required by law, but the validity of the remaining parts, terms,
or provisions shall not be affected and shall continue in full force and effect.
17.Counterparts. This Agreement may be executed in one or more counterparts. Each executed counterpart shall be considered
an original, all of which together shall constitute one instrument binding on the Parties. Consistent with the provisions of Paragraph
13 hereof, the Parties agree that email executed copies of this Agreement shall be deemed effective and enforceable as originals.
18. Employee Acknowledgments.
(a)
The release language contained in this Agreement constitutes, among other things, a waiver of all rights and claims Employee may
have under the Age Discrimination in Employment Act of 1967, as amended (29 U.S.C. § 621, et seq.) (the “ADEA”).
(b)
Employee has twenty-one (21) days from the date Employee is presented with a copy of this Agreement to consider whether to sign
this Agreement. Employee may unilaterally waive this twenty-one (21) day period at Employee’s election, but in no instance may
Employee sign this Agreement before the Separation Date, or it will not be valid. Employee’s signature on this Agreement constitutes
an express waiver of the twenty-one (21) day period if affixed prior to the expiration of that period. The Parties expressly agree that
any revisions or modifications to this Agreement, whether material or immaterial, will not and did not restart this twenty-one (21) day
review period. Employee further acknowledges that the period of time Employee had to consider Employee’s rights and obligations
under this Agreement was reasonable.
7
(c)
Employee may revoke Employee’s release of claims under the ADEA at any time within seven (7) days of Employee’s execution
of this Agreement. Employee’s release of claims under the ADEA shall not become effective or enforceable until this seven (7) day
revocation period has expired without Employee having exercised Employee’s right to revoke Employee’s release of claims under
the ADEA. Any such revocation by Employee must be made in a letter signed by Employee and received by Dean Zikria, with a copy to William
Haddad, at the address set forth in Paragraph 13 by no later than the eighth (8th) day following Employee’s execution of this Agreement.
If Employee does not exercise Employee’s right to revoke Employee’s release of claims under the ADEA during the seven (7)
day revocation period, this entire Agreement will take effect as of the eighth (8th) day following Employee’s execution
of this Agreement. On the other hand, if Employee duly revokes Employee’s release of claims under the ADEA during the seven (7)
day revocation period, this entire Agreement will still take effect as of the eighth (8th) day following Employee’s execution
hereof, except for Employee’s release of claims under the ADEA, and in such case, Employee shall only be entitled to twenty percent
(20%) of the Severance. In either of the foregoing instances, the eighth (8th) day following Employee’s execution of this Agreement
shall be the Agreement’s “Effective Date.”
(d)
Regardless of whether Employee revokes Employee’s release of claims under the ADEA during the seven (7) day revocation period,
under no circumstance shall the Employer be obligated to remit any portion of the Severance or COBRA Payments, nor is Employer required
to fulfill any of its obligations under this Agreement, until (i) the Effective Date of the Agreement (as defined herein) has passed;
and (ii) Employee has returned all Confidential Information and all Employer Property.
(e)
Employee has carefully read and understands all of the terms of this Agreement and agrees and acknowledges that such terms are
fair and reasonable, and are not the result of any fraud, duress, coercion, pressure, or undue influence exercised by or on behalf of
any of the Releasees. Employee has agreed to, and has entered into, this Agreement and all of the terms hereof, knowingly, freely, and
voluntarily. In executing this Agreement, Employee is not relying on, and has not relied on, any representation or statement made by any
of the Releasees or their representatives or attorneys with regard to the subject matter, basis, or effect of the Agreement, other than
as explicitly set forth herein.
(f)
Employee has been, and is hereby, advised by the Employer to consult with an attorney before executing this Agreement.
(g)
Employee is not suffering from any disability or impairment that would render Employee unable to read, consider and/or understand
this Agreement.
8
IN WITNESS WHEREOF, the Parties
hereto have executed this Separation Agreement and General Release.
Melinda Lackey
Valion Bio, Inc.
Print: Melinda Lackey
Print: Lisa Wolf
Date: 10/31/2026
Title: COO/CFO
Sign: /s/ Melinda Lackey
Date: 10/31/2026
Sign: /s/ Lisa Wolf
9
EX-99.1 — PRESS RELEASE, DATED OCTOBER 30, 2026
EX-99.1
Filename: valion_ex9901.htm · Sequence: 3
Exhibit 99.1
Valion Bio Advancing Entolimod into
U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
NIAID-RNCP elects to evaluate the efficacy
of Entolimod on gastrointestinal acute radiation syndrome (“GI-ARS”), after the announcement of positive safety findings
Fully funded study will evaluate Entolimod’s
potential to improve survival rates and gastrointestinal (“GI”) tissue recovery following radiation exposure
Top-line results anticipated in early December,
providing the next key development milestone for Valion Bio’s lead biologic drug candidate and, if positive, will further support
Entolimod’s potential role in government preparedness for radiological and nuclear mass-casualty scenarios
SAN ANTONIO, TX / October 30, 2026 / ACCESS
Newswire -- Valion Bio, Inc. (NASDAQ: VBIO) (“Valion” or the “Company”), a clinical-stage biopharmaceutical company
developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today announced that the Armed Forces
Radiobiology Research Institute (“AFRRI”) will be evaluating the therapeutic efficacy of Entolimod. This phase will evaluate
whether treatment administered after radiation exposure improves survival in a model designed to assess gastrointestinal acute radiation
syndrome (“GI-ARS”).
The therapeutic study is fully funded by the National
Institute of Allergy and Infectious Diseases (“NIAID”)/Radiation and Nuclear Countermeasures Program (“RNCP”)
under an Interagency Agreement with the Uniformed Services University (“USU”)/AFRRI. Top-line results are anticipated in early
December.
The decision to advance the program to the therapeutic
phase comes just days after Valion announced positive safety results. Achieving this milestone uniquely positions Valion Bio, potentially
further strengthening its competitive position, commercial opportunities, and fundamental outlook.
“NIAID’s decision to move into therapeutic
efficacy testing at AFRRI gives Entolimod a clear next milestone following the positive safety findings,” said Dean Zikria, Interim
Chief Executive Officer of Valion Bio. “The central question is now whether treatment after radiation exposure can improve survival
in a model designed to isolate gastrointestinal injury. This fully funded study provides an opportunity to evaluate that potential while
preserving Valion’s capital and generating critical efficacy data to guide Entolimod towards its next stage of development.”
Evaluating Entolimod’s Potential to Improve
Survival Following Radiation Exposure
Entolimod is being developed as a potential medical
countermeasure for both the hematopoietic (or bone marrow) and gastrointestinal (“GI”) forms of acute radiation syndrome (“ARS”).
By shielding roughly 2.5% of the animals’ bone marrow, the upcoming study’s partial-body irradiation model will enable researchers to
differentiate between effects linked to the mitigation of gastrointestinal injury and those associated with recovery.
Mice will receive a single administration of either
Entolimod or saline control 24 hours after radiation exposure and then will be monitored for 30 days. The primary endpoint is survival,
with outcomes to be compared between the treatment and control groups.
“GI-ARS remains a critical challenge in
the development of medical countermeasures,” added Mr. Zikria. “Demonstrating a survival benefit in this model would underscore
a novel and clinically significant milestone for Entolimod and further strengthen its potential role as a medical countermeasure for radiation
emergencies. We would like to thank AFRRI and NIAID for their continued support and look forward to the results from this key study.”
1
About Valion Bio, Inc.
Valion Bio, Inc. (NASDAQ:VBIO) is developing biologics
that activate innate immune pathways for cytoprotection and modulate immune responses in conditions driven by radiation, disease and immune
dysregulation.
The Company’s lead candidate, Entolimod,
is being developed as a potential medical countermeasure for Acute Radiation Syndrome (“ARS”) and has been evaluated in animal
models under the U.S. Food and Drug Administration’s (“FDA”) Animal Rule, which allows the Agency to approve new drugs
and biological products based on animal efficacy studies when human clinical trials are not ethical or feasible, such as in the case of
acute radiation exposure. Entolimod is a novel Toll-like Receptor 5 agonist designed to activate NF-κB signaling pathways associated
with cellular protection, tissue recovery and immune response. The product candidate has received Fast Track and Orphan Drug designations
from the FDA. Valion holds an exclusive, worldwide license from Statera Biopharma to develop and commercialize Entolimod for ARS, radiation-induced
neutropenia, and other indications.
Valion is also advancing Entolasta, a next-generation
TLR5 agonist designed for potential use in broader therapeutic applications, including oncology supportive care. The Company’s pipeline
includes potential programs in neutropenia and immune dysfunction.
Valion’s wholly owned subsidiary, Velocity
Bioworks, is a biologics contract development and manufacturing organization providing development and manufacturing services to Valion
to support its internal pipeline, with the objective of increasing manufacturing control, reducing costs, accelerating development timelines
and strengthening domestic supply-chain security.
For more information, visit www.valionbio.com.
Forward-Looking Statements
This press release may contain “forward-looking
statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained
in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by
the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,”
“expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,”
“predict,” “project,” “target,” “aim,” “should,” “will” “would,”
or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking
statements are based on Valion’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are
difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be
accurate. Forward-looking statements in this press release include, among others, statements regarding: the timing and success of preclinical
and clinical trials and study results, including the AFRRI/NIAID studies described herein; the development and regulatory advancement
of Entolimod under the FDA Animal Rule; the timing and outcome of regulatory or government interactions; the initiation, design,
timing and outcome of investigator-sponsored studies in neutropenia; the development and potential applications of Entolasta; the ability
of the Company to expand the TLR5 platform into oncology supportive care or other indications; and the Company’s ability to obtain
additional capital and the continued listing of the Company’s common stock on the Nasdaq Capital Market. Given these risks and uncertainties,
you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and
other important factors, any of which could cause Valion’s actual results to differ from those contained in the forward-looking
statements, see Valion’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2025, filed
with the SEC on March 30, 2026, under the heading “Risk Factors”; as well as the Company’s subsequent filings with the
SEC. Forward-looking statements contained in this press release are made as of this date, and Valion undertakes no duty to update such
information except as required by applicable law.
Investor
and Media Contact
Stephen Kilmer
(646) 274-3580
stephen.kilmer@valionbio.com
2
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.3
Cover
Oct. 27, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Oct. 27, 2026
Entity File Number
001-41052
Entity Registrant Name
Valion
Bio, Inc.
Entity Central Index Key
0001787740
Entity Tax Identification Number
81-4016391
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
1305 E. Houston Street,
Entity Address, City or Town
San Antonio
Entity Address, State or Province
TX
Entity Address, Postal Zip Code
78205
City Area Code
888
Local Phone Number
276-6888
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common Stock, par value
$0.0001 per share
Trading Symbol
VBIO
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
true
Elected Not To Use the Extended Transition Period
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details
Name:
dei_EntityExTransitionPeriod
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration